|
US5358971A
|
|
Substituted 2-aminotetralins
|
|
US5382596A
|
|
Substituted 2-aminotetralins
|
|
WO9324471A1
|
|
Substituted naphthoxazines useful as dopaminergics
|
|
US5270346A
|
|
Penetration enhancers for transdermal delivery of systemic agents
|
|
US5256661A
|
|
Substituted 2-aminotetralins and pharmaceutical use
|
|
US5278150A
|
|
2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
|
|
US5274003A
|
|
Substituted 2-aminotetralins
|
|
US5256398A
|
|
Composition for determining viability of tissue
|
|
US5206377A
|
|
Compounds useful as antiproliferative agents
|
|
US5268385A
|
|
Method for treating schizophrenia
|
|
US5118704A
|
|
Substituted 2-aminotetralins useful as dopaminergics
|
|
US5177112A
|
|
Substituted 2-aminotetralins
|
|
US5218113A
|
|
N-substituted thiolactams
|
|
US5283343A
|
|
2-aryl substituted N-acetyltryptamines and process of preparing such
|
|
AU8224991A
|
|
Substituted naphthoxazines useful as dopaminergics
|
|
US5234945A
|
|
Method of producing body weight and food intake using a dopamine D2 receptor agonist
|
|
US5118692A
|
|
Penetration enhances for transdermal delivery of systemic agents
|
|
US5234959A
|
|
Penetration enhancers for transdermal delivery of systemic agents
|
|
US5256647A
|
|
Compositions comprising 1-substituted azacycloalkanes
|
|
US5118676A
|
|
Penetration enhancers for transdermal delivery of systemic agents
|
